Drugs / Hyperimmune caprine serum
Hyperimmune caprine serum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00769028 | Dec 2008 → Feb 2011 | systemic sclerosis | Daval International Limited | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperimmune caprine serum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00769028 ↗ |
| Known as | AIMSPRO | “Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.” PMID 24067785 ↗ Sep 2013 |
| Known as | HICS | “Hyperimmune caprine serum (HICS) is a novel biological therapy with potential benefit for skin in established diffuse cutaneous systemic sclerosis.” PMID 28270187 ↗ Mar 2017 |
| Route | Subcutaneous | “by subcutaneous twice weekly injection over 26 weeks” PMID 24067785 ↗ Sep 2013 |